BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

48 related articles for article (PubMed ID: 26467564)

  • 1. Potent anti-tumor effects of EGFR-targeted hybrid peptide on mice bearing liver metastases.
    Gaowa A; Horibe T; Kohno M; Harada H; Hiraoka M; Kawakami K
    Clin Exp Metastasis; 2016 Jan; 33(1):87-95. PubMed ID: 26467564
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhancement of anti-tumor activity of hybrid peptide in conjugation with carboxymethyl dextran via disulfide linkers.
    Gaowa A; Horibe T; Kohno M; Tabata Y; Harada H; Hiraoka M; Kawakami K
    Eur J Pharm Biopharm; 2015 May; 92():228-36. PubMed ID: 25801495
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential response to EGFR- and VEGF-targeted therapies in patient-derived tumor tissue xenograft models of colon carcinoma and related metastases.
    Jin K; Lan H; Cao F; Han N; Xu Z; Li G; He K; Teng L
    Int J Oncol; 2012 Aug; 41(2):583-8. PubMed ID: 22581265
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antitumor effect of FP3 in combination with cetuximab on patient-derived tumor tissue xenograft models of primary colon carcinoma and related lymphatic and hepatic metastases.
    Dong X; Jin K; Hu X; Du F; Lan H; Han N; Ma Z; Xie B; Cui B; Teng L; Cao F
    Int J Mol Med; 2012 Jul; 30(1):126-32. PubMed ID: 22505231
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Noninvasive visualization of tumor growth in a human colorectal liver metastases xenograft model using bioluminescence in vivo imaging.
    Thalheimer A; Korb D; Bönicke L; Wiegering A; Mühling B; Schneider M; Koch S; Riedel SS; Germer CT; Beilhack A; Brändlein S; Otto C
    J Surg Res; 2013 Nov; 185(1):143-51. PubMed ID: 23998649
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A single replacement of histidine to arginine in EGFR-lytic hybrid peptide demonstrates the improved anticancer activity.
    Tada N; Horibe T; Haramoto M; Ohara K; Kohno M; Kawakami K
    Biochem Biophys Res Commun; 2011 Apr; 407(2):383-8. PubMed ID: 21396910
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The membrane-lytic peptides K8L9 and melittin enter cancer cells via receptor endocytosis following subcytotoxic exposure.
    Kohno M; Horibe T; Ohara K; Ito S; Kawakami K
    Chem Biol; 2014 Nov; 21(11):1522-32. PubMed ID: 25444552
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Liver-directed therapies in metastatic colorectal cancer.
    Clark ME; Smith RR
    J Gastrointest Oncol; 2014 Oct; 5(5):374-87. PubMed ID: 25276410
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination of hybrid peptide with biodegradable gelatin hydrogel for controlled release and enhancement of anti-tumor activity in vivo.
    Gaowa A; Horibe T; Kohno M; Sato K; Harada H; Hiraoka M; Tabata Y; Kawakami K
    J Control Release; 2014 Feb; 176():1-7. PubMed ID: 24378440
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cancer treatment using peptides: current therapies and future prospects.
    Thundimadathil J
    J Amino Acids; 2012; 2012():967347. PubMed ID: 23316341
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytotoxic activity to acute myeloid leukemia cells by Antp-TPR hybrid peptide targeting Hsp90.
    Horibe T; Kawamoto M; Kohno M; Kawakami K
    J Biosci Bioeng; 2012 Jul; 114(1):96-103. PubMed ID: 22425524
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting interleukin-4 receptor α with hybrid peptide for effective cancer therapy.
    Yang L; Horibe T; Kohno M; Haramoto M; Ohara K; Puri RK; Kawakami K
    Mol Cancer Ther; 2012 Jan; 11(1):235-43. PubMed ID: 22084165
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel transferrin receptor-targeted hybrid peptide disintegrates cancer cell membrane to induce rapid killing of cancer cells.
    Kawamoto M; Horibe T; Kohno M; Kawakami K
    BMC Cancer; 2011 Aug; 11():359. PubMed ID: 21849092
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.